Clinical Trial Detail

NCT ID NCT02354131
Title Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer (AVANOVA)
Recruitment Active, not recruiting
Gender male
Phase Phase Ib/II
Variant Requirements No
Sponsors Nordic Society for Gynaecologic Oncology
Indications

fallopian tube cancer

peritoneum cancer

ovary epithelial cancer

Therapies

Niraparib

Bevacizumab + Niraparib

Age Groups: senior adult

No variant requirements are available.